Hanew Kunihiko, Tachibana Katsuhiko, Yokoya Susumu, Fujieda Kenji, Tanaka Toshiaki, Igarashi Yutaka, Shimatsu Akira, Tanaka Hiroyuki, Tanizawa Takakuni, Teramoto Akira, Nishi Yoshikazu, Hasegawa Yukihiro, Hizuka Naomi, Hirano Takeki, Fujita Keinosuke
Hanew Endocrine Clinic, Sendai, Japan.
Endocr J. 2006 Apr;53(2):259-65. doi: 10.1507/endocrj.53.259.
In this study, we sent questionnaires to doctors treating severe short stature with severe GH deficiency (GHD) (height SDS (HtSDS) below -4 and all peak GH to provocative stimuli below 2 micro/L) (abbreviated as Severe Case), and obtained effective replies of 51 cases. The clinical characteristics, etiologies, and pathophysiology of these patients were examined. Among the 51 Severe Cases no consanguinity was observed, 44 were IGHD (24 males and 20 females), 3 were GH-1 gene deletion, 2 were Pit-1 gene mutation, and 2 were achondroplasia. HtSDS in these Severe Cases was already remarkably low at 12 (-3.0) and 24 months old (-3.9), while their birth weight and birth length were within normal ranges. Among 44 patients with IGHD, 12 were isolated GHD, and the remaining 32 were combined pituitary hormone deficiency (CPHD). Pituitary MRI was undergone in 25 idiopathic GHD, and abnormal findings (pituitary atrophy, interruption of stalk, and ectopic posterior lobe) were observed in 21 patients with CPHD. More than half of these patients had the history of breech delivery. Three patients with GH-1 gene mutation showed normal pituitary MRI, whereas one of two patients with Pit-1 mutation showed pituitary atrophy and narrowing of pituitary stalk. In conclusion, Severe Cases tended to have CPHD, and the incidence of Severe Case was only 0.6% of total IGHD. Although GHD due to genetic disorders is considered to be extremely rare (0.06% of total IGHD), the incidence reaches high levels (9.8%) among Severe Cases. Growth disorders in these Severe Cases seem to occur soon after delivery. Much earlier diagnosis and hGH treatment are desirable to attain better final height in the Severe Cases. GH-1 and Pit-1 gene analyses are crucial, when genetic abnormalities other than achondroplasia are suspected.
在本研究中,我们向治疗严重生长激素缺乏症(GHD)导致的严重身材矮小(身高标准差积分(HtSDS)低于-4且所有刺激试验的生长激素峰值均低于2μg/L)(简称为重症病例)的医生发放了问卷,并获得了51例有效回复。对这些患者的临床特征、病因及病理生理学进行了研究。在这51例重症病例中,未观察到近亲结婚情况,44例为特发性生长激素缺乏症(IGHD)(男性24例,女性20例),3例为生长激素-1基因缺失,2例为垂体特异性转录因子-1(Pit-1)基因突变,2例为软骨发育不全。这些重症病例在12个月(-3.0)和24个月(-3.9)时身高标准差积分就已显著偏低,而其出生体重和出生身长均在正常范围内。在44例IGHD患者中,12例为单纯生长激素缺乏症,其余32例为联合垂体激素缺乏症(CPHD)。25例特发性生长激素缺乏症患者接受了垂体磁共振成像(MRI)检查,21例CPHD患者观察到异常表现(垂体萎缩、垂体柄中断及垂体后叶异位)。这些患者中超过一半有臀位分娩史。3例生长激素-1基因突变患者垂体MRI表现正常,而2例Pit-1基因突变患者中有1例表现为垂体萎缩及垂体柄变窄。总之,重症病例倾向于患有CPHD,重症病例的发生率仅占IGHD总数的0.6%。尽管因遗传疾病导致的生长激素缺乏症被认为极其罕见(占IGHD总数的0.06%),但在重症病例中的发生率却达到较高水平(9.8%)。这些重症病例的生长障碍似乎在出生后不久就会出现。为了使重症病例获得更好地最终身高,早期诊断和生长激素治疗是很有必要的。当怀疑除软骨发育不全以外的其他遗传异常时,生长激素-1和Pit-1基因分析至关重要。